Oncopeptides AB (STO:ONCO), a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat haematological diseases, announced on Friday the successful completion of enrolment in the pivotal phase 3 study OCEAN for the treatment of relapsed refractory multiple myeloma.
This study includes 450 patients from over 100 hospitals around the world. Top line results are expected to be presented later this year.
According to the company, OCEAN is a randomised, comparative study between melflufen and pomalidomide in patients with relapsed refractory multiple myeloma (RRMM). The patients have been treated with immunomodulatory inhibitors (IMiD) and proteasome inhibitors (PI), they have developed resistance to their last line of therapy and are refractory to lenalidomide (IMiD), the most commonly used drug for the treatment of multiple myeloma. The primary endpoint is Progression Free Survival (PFS).
Based on the pivotal phase 3 data, the company intends to submit a supplemental New Drug Application (sNDA) to the US FDA in the second quarter of 2021, followed by a submission of a Marketing Authorisation Application (MAA) in Europe.
Emmaus Life Sciences' Endari label enhancements receive US FDA approval
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress
Cumberland Pharmaceuticals reports ifetroban Phase 2 DMD heart disease trial results
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma